Chiun Hsu

18.5k total citations · 3 hit papers
226 papers, 7.4k citations indexed

About

Chiun Hsu is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Chiun Hsu has authored 226 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 111 papers in Oncology, 92 papers in Hepatology and 52 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Chiun Hsu's work include Hepatocellular Carcinoma Treatment and Prognosis (84 papers), Cancer Immunotherapy and Biomarkers (35 papers) and Pancreatic and Hepatic Oncology Research (32 papers). Chiun Hsu is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (84 papers), Cancer Immunotherapy and Biomarkers (35 papers) and Pancreatic and Hepatic Oncology Research (32 papers). Chiun Hsu collaborates with scholars based in Taiwan, United States and South Korea. Chiun Hsu's co-authors include Ann‐Lii Cheng, Ying‐Chun Shen, Chih‐Hung Hsu, Yu‐Yun Shao, Masatoshi Kudo, Da‐Liang Ou, Su Pin Choo, Stephen L. Chan, Zhong‐Zhe Lin and James Chih‐Hsin Yang and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Chiun Hsu

221 papers receiving 7.3k citations

Hit Papers

Comparative safety of imm... 2017 2026 2020 2023 2018 2020 2017 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
    2018 416 citations Chiun Hsu et al. profile →
  2. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
    2020 386 citations Ann‐Lii Cheng, Chiun Hsu et al. Journal of Hepatology profile →
  3. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
    2017 300 citations Chiun Hsu et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Chiun Hsu 3.2k 2.6k 1.9k 1.5k 1.4k 226 7.4k
David J. Pinato 3.0k 0.9× 2.2k 0.9× 1.3k 0.7× 1.4k 0.9× 1.3k 0.9× 233 6.3k
Jean‐Frédéric Blanc 2.0k 0.6× 2.9k 1.1× 1.8k 0.9× 1.8k 1.1× 1.2k 0.8× 164 6.8k
Li‐Tzong Chen 2.6k 0.8× 1.2k 0.4× 2.4k 1.2× 1.2k 0.8× 1.8k 1.3× 296 7.3k
Tae‐You Kim 4.3k 1.3× 1.5k 0.6× 2.0k 1.0× 680 0.4× 2.5k 1.8× 189 7.6k
Paul Ruff 6.4k 2.0× 1.8k 0.7× 1.4k 0.7× 779 0.5× 2.6k 1.8× 155 8.9k
Eric Assénat 7.2k 2.2× 1.6k 0.6× 1.9k 1.0× 2.0k 1.3× 2.5k 1.7× 176 10.2k
Gamze Karaca 4.6k 1.4× 1.1k 0.4× 3.4k 1.8× 1.5k 1.0× 1.2k 0.8× 40 9.6k
Shukui Qin 5.2k 1.6× 5.3k 2.0× 2.7k 1.4× 1.9k 1.3× 3.8k 2.7× 337 12.0k
Daniel H. Palmer 5.3k 1.7× 3.3k 1.3× 2.4k 1.2× 2.4k 1.6× 3.0k 2.1× 219 11.7k
Robert R. McWilliams 5.9k 1.8× 742 0.3× 2.4k 1.2× 1.1k 0.7× 1.9k 1.3× 206 8.4k

Countries citing papers authored by Chiun Hsu

Since Specialization
Citations

This map shows the geographic impact of Chiun Hsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chiun Hsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chiun Hsu more than expected).

Fields of papers citing papers by Chiun Hsu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chiun Hsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chiun Hsu. The network helps show where Chiun Hsu may publish in the future.

Co-authorship network of co-authors of Chiun Hsu

This figure shows the co-authorship network connecting the top 25 collaborators of Chiun Hsu. A scholar is included among the top collaborators of Chiun Hsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chiun Hsu. Chiun Hsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chan, Stephen L., et al.. (2025). New targets and new drugs for hepatobiliary cancers. Journal of Hepatology. 84(1). 213–228. 2 indexed citations
2.
Chen, Yu‐Hsin, Da‐Liang Ou, Chia‐Lang Hsu, et al.. (2024). Regorafenib enhances M1/M2 macrophage polarization by inhibiting the secretion of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma. Life Sciences. 358. 123147–123147.
3.
Lin, Zhong‐Zhe, Mickey C.‐T. Hu, Chiun Hsu, et al.. (2023). Synergistic efficacy of telomerase-specific oncolytic adenoviral therapy and histone deacetylase inhibition in human hepatocellular carcinoma. Cancer Letters. 556. 216063–216063. 7 indexed citations
4.
Hsu, Chia‐Lang, et al.. (2023). Genomic and Transcriptomic Landscape of an Oral Squamous Cell Carcinoma Mouse Model for Immunotherapy. Cancer Immunology Research. 11(11). 1553–1567. 9 indexed citations
5.
6.
Sangro, Bruno, Ignacio Melero, Chiun Hsu, et al.. (2017). Nivolumab in Sorafenib-Naive and -Experienced Patients With Advanced Hepatocellular Carcinoma (HCC): Survival, Hepatic Safety, and Biomarker Assessments in CheckMate 040. UCL Discovery (University College London). 12 indexed citations
7.
Hsiue, Emily Han-Chung, Chiun Hsu, Li‐Hui Tseng, Tzu‐Pin Lu, & Kuan‐Ting Kuo. (2017). Epithelioid Trophoblastic Tumor Around an Abdominal Cesarean Scar: A Pathologic and Molecular Genetic Analysis. International Journal of Gynecological Pathology. 36(6). 562–567. 12 indexed citations
8.
Chen, Bang‐Bin, Chao‐Yu Hsu, Chih‐Wei Yu, et al.. (2016). Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma. European Radiology. 27(7). 3069–3079. 17 indexed citations
9.
Hsu, Chiun, Liang‐In Lin, Yu‐Che Cheng, et al.. (2015). Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression. Clinical Cancer Research. 22(10). 2555–2564. 40 indexed citations
10.
Liu, Tsang‐Wu, Jyh‐Ming Chow, Chang‐Fang Chiu, et al.. (2015). Gap in the Intensity of End-of-Life Care between Younger and Older Taiwanese Adult Cancer Patients may not Reflect Younger Patients’ Preferences. SHILAP Revista de lepidopterología. 2 indexed citations
11.
12.
Wu, Pei‐Chun, Jeng‐Wei Lu, Jer‐Yen Yang, et al.. (2014). H3K9 Histone Methyltransferase, KMT1E/SETDB1, Cooperates with the SMAD2/3 Pathway to Suppress Lung Cancer Metastasis. Cancer Research. 74(24). 7333–7343. 56 indexed citations
13.
Yang, Shih‐Hung, Yu‐Hsuan Kuo, Yu‐Wen Tien, et al.. (2011). Inferior Survival of Advanced Pancreatic Cancer Patients Who Received Gemcitabine-Based Chemotherapy but Did Not Participate in Clinical Trials. Oncology. 81(3-4). 143–150. 13 indexed citations
14.
Ou, Da‐Liang, Ying‐Chun Shen, Sung‐Liang Yu, et al.. (2010). Induction of DNA Damage-Inducible Gene GADD45β Contributes to Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Cells. Cancer Research. 70(22). 9309–9318. 68 indexed citations
15.
16.
Hsu, Chiun, Chao A. Hsiung, Ih‐Jen Su, et al.. (2008). A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial. Hepatology. 47(3). 844–853. 230 indexed citations
17.
Hsu, Chiun. (2008). In Vivo Efficacy of Nemonoxacin in a Mouse Pulmonary Infection Model. 46th Annual Meeting. 5 indexed citations
18.
Hsu, Chiun. (2008). In Vivo Efficacy of Nemonoxacin in a Mouse Protection Model. 46th Annual Meeting. 5 indexed citations
19.
Ou, Da‐Liang, Ying‐Chun Shen, Sung‐Liang Yu, et al.. (2008). Potential synergistic anti-tumor effects between sorafenib and the MEK inhibitor CI1040 in hepatocellular carcinoma (HCC). Cancer Research. 68. 1435–1435. 1 indexed citations
20.
Chao, You‐Chen, Ton-Ho Young, Haoning Tang, & Chiun Hsu. (1997). Alcoholism and Alcoholic Organ Damage and Genetic Polymorphisms of Alcohol Metabolizing Enzymes in Chinese Patients. Hepatology. 25(1). 112–117. 91 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David J. Pinato Breakdown of academic impact, for papers by Jean‐Frédéric Blanc Breakdown of academic impact, for papers by Li‐Tzong Chen Breakdown of academic impact, for papers by Tae‐You Kim Breakdown of academic impact, for papers by Paul Ruff Breakdown of academic impact, for papers by Eric Assénat Breakdown of academic impact, for papers by Gamze Karaca Breakdown of academic impact, for papers by Shukui Qin Breakdown of academic impact, for papers by Daniel H. Palmer Breakdown of academic impact, for papers by Robert R. McWilliams
Rankless by CCL
2026